Buys | $0 | 0 | 0 |
Sells | $10,261,752 | 8 | 100 |
Coleman Mark | director | 0 | $0 | 2 | $789,107 | $-789,107 |
Saad Mark E | director | 0 | $0 | 1 | $1.01M | $-1.01M |
Pizzie Nick | Chief Financial Officer | 0 | $0 | 2 | $1.95M | $-1.95M |
Jacobson Mark L. | Chief Operating Officer | 0 | $0 | 3 | $6.52M | $-6.52M |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly …
Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $10.26M worth of Axsome Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $242,389 and sold $6.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,950 shares for transaction amount of $147,350 was made by JEFFS ROGER (director) on 2021‑11‑19.
2025-02-14 | Sale | Pizzie Nick | Chief Financial Officer | 3,000 0.0062% | $131.07 | $393,210 | -4.14% | |
2025-02-13 | Sale | Pizzie Nick | Chief Financial Officer | 12,000 0.0244% | $129.86 | $1.56M | -4.50% | |
2024-09-11 | Sale | Saad Mark E | director | 11,016 0.0226% | $91.31 | $1.01M | +2.92% | |
2024-08-09 | Sale | Jacobson Mark L. | Chief Operating Officer | 47,739 0.1009% | $84.26 | $4.02M | +11.55% | |
2024-05-29 | Sale | Coleman Mark | director | 5,248 0.011% | $75.14 | $394,333 | +19.63% | |
2024-05-29 | Sale | Jacobson Mark L. | Chief Operating Officer | 7,910 0.0165% | $74.31 | $587,813 | +19.63% | |
2024-05-28 | Sale | Coleman Mark | director | 5,249 0.0108% | $75.21 | $394,775 | +17.18% | |
2024-04-01 | Sale | Jacobson Mark L. | Chief Operating Officer | 24,662 0.0522% | $77.24 | $1.9M | +14.40% | |
2024-03-15 | Sale | JEFFS ROGER | director | 2,347 0.0047% | $71.61 | $168,062 | +15.50% | |
2024-03-14 | Sale | JEFFS ROGER | director | 16,976 0.036% | $69.70 | $1.18M | +25.01% | |
2023-09-15 | Sale | Coleman Mark | director | 29,588 0.0626% | $75.18 | $2.22M | +1.06% | |
2021-11-19 | JEFFS ROGER | director | 3,950 0.0109% | $37.30 | $147,350 | +3.44% | ||
2021-11-18 | Coleman Mark | director | 1,430 0.0037% | $35.09 | $50,181 | +4.03% | ||
2021-11-18 | Pizzie Nick | CHIEF FINANCIAL OFFICER | 955 0.0025% | $35.26 | $33,676 | +4.03% | ||
2021-11-17 | Saad Mark E | director | 3,300 0.0087% | $34.52 | $113,922 | +7.00% | ||
2021-05-12 | Coleman Mark | director | 500 0.0014% | $58.15 | $29,075 | -38.38% | ||
2020-06-29 | Coleman Mark | director | 650 0.0018% | $78.50 | $51,025 | -5.10% | ||
2020-06-29 | Pizzie Nick | Chief Financial Officer | 777 0.0021% | $76.64 | $59,549 | -5.10% | ||
2019-09-26 | Pizzie Nick | Chief Financial Officer | 2,180 0.0063% | $24.80 | $54,064 | +210.19% | ||
2019-06-26 | Coleman Mark | director | 15,800 0.0481% | $23.10 | $364,980 | +145.30% |
Pizzie Nick | Chief Financial Officer | 42187 0.0865% | $5.31M | 6 | 2 | +84.72% |
Coleman Mark | director | 14600 0.0299% | $1.84M | 7 | 3 | +51.01% |
Saad Mark E | director | 10002 0.0205% | $1.26M | 2 | 1 | +23.86% |
JEFFS ROGER | director | 120756 0.2476% | $15.2M | 1 | 2 | +3.44% |
Kaye Randall | Chief Medical Officer | 6022 0.0123% | $758,169.80 | 1 | 0 | <0.0001% |
$159,914,414 | 243 | 18.52% | $6.12B | |
$211,610,344 | 91 | 38.45% | $7.52B | |
$52,263,649 | 70 | 1.18% | $4.87B | |
$108,876,545 | 67 | 72.81% | $7.92B | |
$42,463,802 | 57 | 17.85% | $7.76B |
Increased Positions | 154 | +47.68% | 5M | +13.34% |
Decreased Positions | 136 | -42.11% | 6M | -15.41% |
New Positions | 62 | New | 2M | New |
Sold Out Positions | 40 | Sold Out | 2M | Sold Out |
Total Postitions | 341 | +5.57% | 38M | -2.07% |
Rtw Investments, Lp | $493,902.00 | 8.27% | 4.05M | -138,192 | -3.3% | 2024-12-31 |
Vanguard Group Inc | $475,751.00 | 7.96% | 3.9M | -92,866 | -2.32% | 2024-12-31 |
Blackrock, Inc. | $430,756.00 | 7.21% | 3.53M | +135,015 | +3.97% | 2024-12-31 |
Fairmount Funds Management Llc | $179,084.00 | 3% | 1.47M | -891,094 | -37.76% | 2024-12-31 |
Bvf Inc/Il | $169,219.00 | 2.83% | 1.39M | +342,064 | +32.7% | 2024-12-31 |
Fmr Llc | $121,964.00 | 2.04% | 1M | -87,641 | -8.05% | 2024-12-31 |
Ra Capital Management, L.P. | $121,910.00 | 2.04% | 1M | 0 | 0% | 2024-12-31 |
Macquarie Group Ltd | $117,527.00 | 1.97% | 964,047 | -31,240 | -3.14% | 2024-12-31 |
State Street Corp | $115,479.00 | 1.93% | 947,251 | +30,443 | +3.32% | 2024-12-31 |
Geode Capital Management, Llc | $111,248.00 | 1.86% | 912,538 | +4,079 | +0.45% | 2024-12-31 |